2. Disease Areas
  3. Respiratory Disease
  4. Lower Respiratory Inflammation

Lower Respiratory Inflammation

Lower respiratory inflammation is commonly triggered by infections such as bronchitis, bronchiolitis, or pneumonia, resulting in symptoms including cough, shortness of breath, chest pain, and fatigue.

 

Lower Respiratory Inflammation (71):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B0809
    Theophylline 58-55-9 99.97%
    Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research.
    Theophylline
  • HY-P990774
    Verekitug 2768386-15-6
    Verekitug (ASP-7266; TRAB-1; UPB-101) is a human monoclonal antibody targeting the thymic stromal lymphopoietin receptor (TSLPR), with a mean half-life of approximately 20 days. At doses of Verekitug ≥100 mg, complete and sustained TSLPR-specific occupancy is achieved, and the antibody does not bind to IL-7Rα. By inhibiting TSLP-driven inflammatory responses, Verekitug blocks TSLP-induced cell proliferation and TARC expression, while reducing fractional exhaled NO levels, blood eosinophil counts, and levels of IL-5 and IgE. Verekitug significantly improves scores for nasal polyps, nasal congestion and olfactory dysfunction, with favorable safety and good tolerability; potential adverse reactions include headache, upper respiratory tract infection, sinusitis and nasopharyngitis. Verekitug is used in relevant studies on asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
    Verekitug
  • HY-P990217
    Anti-Mouse IL-23 p19 Antibody (G23-8) 99.14%
    Anti-Mouse IL-23 p19 Antibody (G23-8) is a rat-derived anti-mouse IL-23 p19 IgG1 monoclonal antibody. Anti-Mouse IL-23 p19 Antibody (G23-8) alleviates inflammation by restoring CLDN8 expression. Anti-Mouse IL-23 p19 Antibody (G23-8) can be used for research on inflammation conditions such as colitis and asthma.
    Anti-Mouse IL-23 p19 Antibody (G23-8)
  • HY-P99053
    Tralokinumab 1044515-88-9 99.12%
    Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis.
    Tralokinumab
  • HY-P990748
    Lunsekimig 2770858-49-4 99.00%
    Lunsekimig (SAR443765) is an anti-TSLP/IL13/ALB nonobody composed of 5 sequentially linked variable region heavy chains. Lunsekimig decreases blood eosinophils and lowers plasma levels of IL-5, eotaxin-3, and IgE. Lunsekimig also improves lung function. Lunsekimig can be used for the study and treatment of type 2 inflammatory asthma.
    Lunsekimig
  • HY-134092
    N-Methyl Leukotriene C4 131391-65-6
    N-Methyl Leukotriene C4 (N-Methyl-LTC4) is a non-metabolizable LTC4 analog and a selective cysteinyl leukotriene receptor 2 (CysLT2) agonist, with an EC50 of 46.1 nM for mouse CysLT2 and an EC50 value of 122.3 nM for human CysLT2. N-Methyl Leukotriene C4 shows low potency against CysLT1. N-Methyl Leukotriene C4 activates human and mouse CysLT2 receptors, triggering calcium signaling, β-arrestin-2 binding to phosphorylated receptors, vascular leakage, hypotension, tachycardia, contraction of guinea pig ileum and trachea, mild bronchoconstriction, as well as hypertension associated with peripheral vasoconstriction. N-Methyl Leukotriene C4 can be used in research on asthma, rhinitis, sinusitis, cerebral inflammation and edema, pulmonary arterial hypertension, and cardiovascular diseases.
    N-Methyl Leukotriene C4
  • HY-P992034
    APG808
    APG808 (PR001) is an anti-human IL-4Rα monoclonal antibody. APG808 binds to IL-4Rα, prevents IL-13Rα1/IL-4Rα heterodimer formation, and disrupts IL-13 and IL-4 mediated signaling. APG808 ablates Fc and complement effector functions. APG808 can be used for the research of chronic obstructive pulmonary disease, asthma, atopic dermatitis.
    APG808
  • HY-183885
    MPI3 890648-84-7
    MPI3 is a reversible covalent SARS-CoV-2 MPro inhibitor with an enzymatic IC50 of 8.5 nM. MPI3 can be used for the research of covid-19.
    MPI3
  • HY-19979
    RCM-1 339163-65-4 98.56%
    RCM-1 is a forkhead box M1 (FOXM1) inhibitor with an EC50 of 0.72 μM in U2OS cells. RCM-1 blocks the nuclear localization and increased the proteasomal degradation of FOXM1. RCM-1 can be used for asthma and other chronic airway diseases research.
    RCM-1
  • HY-142021
    Z-Leu-Arg-AMC 156192-32-4 99.24%
    Z-Leu-Arg-AMC is a fluorogenic peptide substrate for cysteine proteases (e.g., Cathepsin) (Ex=350 nm，Em=460 nm). Z-Leu-Arg-AMC is preferentially cleaved by Cathepsin K and S under weakly acidic conditions, while its hydrolysis relies on residual Cathepsin S activity at neutral pH. Z-Leu-Arg-AMC serves as a substrate for recombinant Sphenophorus levis Cathepsin L, falcipain-2, falcipain-3, berghepain-2, knowlepain-2, vivapain-2, as well as falcipain-2 chimeras and constructs. It enables quantitative detection of cysteine protease activity in human inflammatory bronchoalveolar lavage fluid via fluorescence generation. Z-Leu-Arg-AMC can be used in research related to pulmonary inflammatory diseases and malaria.
    Z-Leu-Arg-AMC
  • HY-N0732
    Jolkinolide B 37905-08-1 99.65%
    Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis.
    Jolkinolide B
  • HY-P990213
    Anti-Mouse/Human IL-5 Antibody (TRFK5)
    Anti-Mouse/Human IL-5 Antibody (TRFK5) is a rat-derived anti-mouse IL-5 IgG1 κ type antibody inhibitor. Anti-Mouse/Human IL-5 Antibody (TRFK5) can significantly decrease eosinophils. Anti-Mouse/Human IL-5 Antibody (TRFK5) shows potent anti- inflammation effect on pulmonary inflammation and asthma.
    Anti-Mouse/Human IL-5 Antibody (TRFK5)
  • HY-N3519
    Platycodin D3 67884-03-1 98.91%
    Platycodin D3 is a triterpenoid saponin that can be found in Platycodon grandiflorum. Platycodin D3 exhibits multiple activities including anti-inflammation, regulation of airway mucus secretion, improvement of asthmatic airway inflammation and remodeling, and inhibition of hepatitis C virus (HCV) replication. The IC50 value of Platycodin D3 against HCV NS5B RNA-dependent RNA polymerase is 8 μg/mL. Platycodin D3 can be used in studies related to asthma, hepatitis C virus infection and inflammatory diseases.
    Platycodin D3
  • HY-157536
    SMT-738 2862851-15-6 98.47%
    SMT-738 is a bacterial bactericide. SMT-738 targets the small molecules responsible for lipoprotein transport in Enterobacteriaceae, causing abnormal lipoprotein localization and bacterial cell death. SMT-738 inhibits the growth of E. coli and K. pneumoniae. SMT-738 reduces bacterial loads in mouse models of urinary tract infection, bloodstream infection, and pulmonary infection caused by Enterobacterales. SMT-738 can be used in the research of Enterobacteriaceae infections, urinary tract infections, bloodstream infections, and pneumonia.
    SMT-738
  • HY-Y1366
    Hydroxyacetone 116-09-6 98.93%
    Hydroxyacetone is a toxic compound. Hydroxyacetone can be isolated from e-cigarette aerosols. Hydroxyacetone reduces the activity of cellular Mitochondrial reductase (with an IC50 of 5.53 mg/mL for mitochondrial reductase in BEAS-2B cells) and increases ROS levels. Hydroxyacetone induces mitochondrial stress and oxidative damage. Hydroxyacetone induces destabilization of F-actin. At high concentrations, Hydroxyacetone promotes cell rounding and Apoptotic body formation. Hydroxyacetone exerts toxic effects on cells including airway epithelial cells and possesses respiratory toxicity potential.\n
    Hydroxyacetone
  • HY-P990090
    Rademikibart 2648260-80-2 99.13%
    Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα and IL-4Rα inhibitor with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and thymus activation regulated chemokine (TRAC) production. Rademikibart can be used for the research of atopic dermatitis and asthma.
    Rademikibart
  • HY-135490
    Reproterol 54063-54-6 98.94%
    Reproterol is a selective β2-adrenoceptor agonist and cAMP phosphodiesterase (PDE) inhibitor. Reproterol inhibits adenylate cyclase-induced phosphodiesterase activity. Reproterol inhibits histamine release from mast cells. Reproterol is applicable to research related to asthma.
    Reproterol
  • HY-133159
    Resolvin E2 865532-70-3 98.5%
    Resolvin E2 ((-)-Resolvin E2) is an endogenous lipid mediator produced from eicosapentaenoic acid (EPA) under the catalysis of 5-lipoxygenase (5-LOX), and its production increases in hypoxic environments. Resolvin E2 antagonizes BLT1, partially activates ChemR23, and promotes ubiquitin-proteasome-mediated degradation of COX-2. Resolvin E2 reduces the production of prostaglandin E2, blocks polymorphonuclear leukocyte infiltration, and promotes the resolution of airway inflammation. Resolvin E2 ameliorates lipopolysaccharide (LPS) (HY-D1056)-induced depressive-like behaviors. Resolvin E2 can be used in research related to depression, murine peritonitis, neonatal asthma, and other conditions.
    Resolvin E2
  • HY-114495
    Caerulomycin A 21802-37-9 98.0%
    Caerulomycin A is an orally active immunomodulator and antimicrobial agent. Caerulomycin A targets Smad3, STAT1 and GATA-3. Caerulomycin A downregulates GATA-3 expression, inhibits Th2 cell differentiation and Th2 cytokine production, reduces IgE levels, and alleviates pulmonary inflammatory responses and eosinophil infiltration. Caerulomycin A ameliorates collagen-induced arthritis symptoms, reduces joint inflammation and synovitis, and decreases the levels of proinflammatory cytokines in joints. Caerulomycin A inhibits the growth of some filamentous fungi, yeasts and specific bacteria. Caerulomycin A can be used in research related to arthritis and asthma.
    Caerulomycin A
  • HY-A0130
    Sulfalene 152-47-6 99.73%
    Sulfalene (Sulfametopyrazine) is an orally active antimalarial agent. Sulfalene competes with para-aminobenzoic acid in plasmodial and bacterial folic acid synthesis pathways. Sulfalene reduces trachoma-associated pathological changes. Sulfalene can be used for the research of acute falciparum malaria, Schistosoma mansoni infection, trachoma, chronic bronchitis, and bacteriuria in pregnancy.
    Sulfalene